Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal (updated)

Mirati Therapeutics

08/10/2023 22:54

(Adds details from statement in paragraph 2, 3. Changes story
identifier)
       Oct 8 (Reuters) - Bristol-Myers Squibb  BMY.N  is set to
acquire cancer drugmaker Mirati Therapeutics  MRTX.O  for $58
per share in cash, representing $4.8 billion equity value. 
    Bristol-Myers Squibb will finance the transaction with a
combination of cash and debt. 
    The transaction is expected to be dilutive to Bristol-Myers
Squibb's non-GAAP earnings per share by approximately 35 cents
per share in the first 12 months after the transaction closes.
        
  
        
  

 (Reporting by Dimpal Gulwani; Editing by Lisa Shumaker)
 ((Dimpal.Gulwani@thomsonreuters.com;))